Company: DNLI
Filing Date: 2025-04-17
Form Type: DEF 14A
Source: 0001714899-25-000087
Chunk: 24

Company: Denali Therapeutics Inc.
Filing Date: 2025-04-17
Form: DEF 14A
Chunk 24
---
 of our compensation committee meet the requirements for independence under current Nasdaq listing standards and SEC rules and regulations. Each member of the compensation committee is also a non-employee director, as defined pursuant to Rule 16b-3 promulgated under the Exchange Act. The purpose of our compensation committee is to oversee our compensation policies and plans and benefit programs and to discharge the responsibilities of our board of directors relating to compensation of our executive officers. The responsibilities of our compensation committee include, among other things:

• overseeing our overall compensation philosophy and compensation policies and plans and benefit programs;

• reviewing and approving or recommending to the board of directors for approval compensation for our executive officers and directors;

• preparing the compensation committee report that the SEC will require to be included in our annual proxy statement; and

• administering our equity compensation plans.

Our compensation committee operates under a written charter that satisfies the Nasdaq listing standards. A copy of the charter of our compensation committee is available on our website at https://denalitherapeutics.com/investors in the Corporate Governance section of our Investor & Media Relations web page.

#### Corporate Governance and Nominating Committee
The members of our corporate governance and nominating committee are detailed in the table above. All members of our corporate governance and nominating committee meet the requirements for independence under the Nasdaq listing standards and SEC rules and regulations. Mr. Baker will join our corporate governance and nominating committee after his election to our board of directors effective as of the Annual Meeting. Mr. Baker meets the requirements for independence under the Nasdaq listing standards and SEC rules and regulations. Dr. Tessier-Lavigne will cease serving as a member of our corporate governance and nominating committee as of the Annual Meeting.

The responsibilities of our corporate governance and nominating committee include, among other things:

• identifying, evaluating and making recommendations to our board of directors regarding nominees for election to our board of directors and its committees;

• considering and making recommendations to our board of directors regarding the composition of our board of directors and its committees;

• reviewing developments in corporate governance practices;

• evaluating the adequacy of our corporate governance practices and reporting; and

• evaluating the performance of our board of directors and of individual directors.

Our corporate governance and nominating committee operates under a written charter that satisfies the Nasdaq listing standards. A copy of the charter of our corporate governance and nominating committee is available on our website at https://denalitherapeutics.com/investors in the Corporate Governance section of our Investor & Media Relations web page.

<div align